Literature DB >> 23993122

Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure.

Elisa A Bradley1, Murali Chakinala, Joseph J Billadello.   

Abstract

A subset of adult patients with an open atrial septal defect (ASD) have pulmonary arterial hypertension (PAH). We sought to identify predictors of response to PAH-specific medical therapy in this group. Invasive hemodynamic and clinical parameters from 12 patients with an open ASD and PAH (pulmonary vascular resistance [PVR], 8.8 ± 1.2 Wood units; mean pulmonary artery pressure, 55 ± 6 mm Hg; Qp:Qs ratio, 1.1 ± 0.1; and 6-minute walk test distance of 1,046 ± 116 feet) were analyzed. Responders (n = 5) underwent successful ASD closure at 1.3 ± 0.3 years after initiation of medical therapy and were characterized by >30% reduction in PVR (7.2 ± 1.5 to 4.6 ± 0.9 Wood units) versus <20% in nonresponders (n = 7; 9.9 ± 1.7 to 8.2 ± 1.5 Wood units, p <0.03), increased 6-minute walk test distance (1,087 ± 174 vs 1,405 ± 109 feet, p = 0.05), and higher Qp:Qs ratio after therapy (1.9 ± 0.2 vs 1.1 ± 0.2, p <0.02). Body mass index was a significant clinical predictor of response (23.3 ± 1.9 vs 30.0 ± 2.1 kg/m(2), p <0.05) and the change in arterial saturation with exercise correlated inversely with change in PVR (r = -0.739, p <0.01). In conclusion, medical therapy led to a significant improvement in hemodynamic and clinical parameters in a subset of patients with an open ASD and PAH, who were able to safely undergo delayed ASD closure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23993122     DOI: 10.1016/j.amjcard.2013.07.027

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

1.  Improvement of pulmonary arterial hypertension following medication and shunt closure in a BMPR2 mutation carrier with atrial septal defect.

Authors:  Hiroshi Suzuki; Haruo Hanawa; Tsukasa Torigoe; Seiichi Sato
Journal:  J Cardiol Cases       Date:  2017-04-26

Review 2.  "Treat and repair" strategy for shunt lesions: a critical review.

Authors:  Balaji Arvind; Jay Relan; Shyam S Kothari
Journal:  Pulm Circ       Date:  2020-04-09       Impact factor: 3.017

3.  Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series.

Authors:  Sarah Blissett; David Blusztein; Vaikom S Mahadevan
Journal:  Eur Heart J Case Rep       Date:  2020-11-07

4.  Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension.

Authors:  Yoichi Takaya; Teiji Akagi; Ichiro Sakamoto; Hideaki Kanazawa; Gaku Nakazawa; Tsutomu Murakami; Atsushi Yao; Mamoru Nanasato; Mike Saji; Mitsugu Hirokami; Yasushi Fuku; Shinobu Hosokawa; Norio Tada; Kensuke Matsumoto; Masao Imai; Koji Nakagawa; Hiroshi Ito
Journal:  Heart       Date:  2021-06-15       Impact factor: 5.994

5.  Clinical Outcome of Closure of a Small Atrial Septal Defect in a Patient with Pulmonary Arterial Hypertension.

Authors:  Masahiko Umei; Akihito Saito; Katsura Soma; Toshiro Inaba; Masae Uehara; Issei Komuro; Atsushi Yao
Journal:  Intern Med       Date:  2021-08-31       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.